palbociclib
Pfizer's Ibrance Shows Benefit in Rare Appendix Cancer Study but Follow-on Research a Challenge
Premium
The efficacy seen in a small study, especially in GNAS-mutated tumors, could influence care, but the rarity of the cancer is a challenge for further investigations.
Pfizer Oncology Revenues Fall 6 Percent as Firm Anticipates Seagen Acquisition
Several of Pfizer's precision oncology products including Ibrance, Xalkori, and Braftovi saw declines in Q3.
Pfizer Oncology Revenues Fall 4 Percent in Q2; Officials Highlight Encouraging Data From Trials
Executives said the firm's acquisition of Seagen and advancement of new breast cancer candidates will help refocus its efforts in oncology.
No Benefit for First-Line CDK4/6 Therapy Over Second Line in Advanced Breast Cancer Patients
Premium
Giving CDK4/6 inhibitors with endocrine therapy at the outset did not provide an outcome advantage over waiting but did increase toxicities and costs.